Drug Profile
Research programme: Universal influenza vaccine - Sumitomo Pharma/National Istitute of Biomedical Innovation
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator National Institute of Biomedical Innovation; Sumitomo Dainippon Pharma
- Developer National Institute of Biomedical Innovation; Sumitomo Pharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections